Taysha Gene Therapies Inc Investor Relations Material

Taysha Gene Therapies, Inc. is a gene therapy company focused on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.